Keywords: Tumors (Post-Treatment), Quantitative Imaging, Habitat imaging
Motivation: The lack of in vivo and noninvasive biomarkers to quantify tumor microenvironment (TME) normalization hinders the evaluation of bevacizumab (BEV) therapy response in glioblastoma (GBM).
Goal(s): To quantify TME normalization during BEV therapy in GBM by conventional and multiparametric MRI (mpMRI).
Approach: The MRI-based habitats were generated by Gaussian mixture model in patient-derived GBM models. Spatial-paired analyses of MRI, histology, and single-cell RNA sequencing were performed to validate the effetiveness of habitats.
Results: A total of eight habitats were generated to quantify TME normalization spatiotemporally. Habitat7 was strongly correlated with TME normalization-associated phenotypes including pericyte coverage, hypoxia and immune cell infiltration.
Impact: We developed and validated a quantitative mpMRI-based biomarker to characterize TME normalization in GBM. This may provide a new in vivo approach for precise evaluation of BEV therapy response in GBM noninvasively.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords